RxDoctor Payments Data

Chunqiu Hou, MD

Internal Medicine · Milton, MANPI 1073740528

Payments from drug & device makers

$1,512in general payments, 2019–2025

Across 66 payments — averaging $22.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$316
  • E.r. Squibb & Sons, L.L.C.$200
  • AstraZeneca$187
  • Pfizer$170
  • Merck$94
  • Novo Nordisk$82
  • plus $463 from 12 others

What the payments were for

  • Food & beverage$1,512100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,512 in reported general payments places this provider in the 85th percentile of 4,983 internal medicine providers in Massachusetts.

See all internal medicine providers in Massachusetts

Medicare billing

Part B allowed, 2024
$170,132
Medicare patients
345
Services billed
1,868

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide166$166,509
EliquisApixaban152$164,765
JardianceEmpagliflozin105$97,579
XeljanzTofacitinib Citrate12$68,293
Breztri AerosphereBudesonide/Glycopyr/Formoterol78$46,813
JanuviaSitagliptin Phosphate48$41,513
XareltoRivaroxaban20$29,687
TrulicityDulaglutide12$23,743
RybelsusSemaglutide16$16,947
Praluent PenAlirocumab14$10,960
Repatha SureclickEvolocumab19$10,557
Atorvastatin Calcium720$9,921
Breo ElliptaFluticasone/Vilanterol23$9,358
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate17$7,932
Valsartan199$7,272

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Xeljanz$170$233,058164 claims
Novo NordiskOzempic, Rybelsus$82$183,456182 claims
Boehringer IngelheimJardiance, Tradjenta$20$103,458117 claims
AstraZenecaBreztri Aerosphere, Symbicort$187$52,24995 claims
MerckJanuvia$94$41,51348 claims
Johnson & JohnsonXarelto$58$29,68720 claims
Lilly USA, LLCTrulicity$20$23,74312 claims
GSKBreo Ellipta$31$9,35823 claims
AbbVieSynthroid$48$2,16633 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,983 internal medicine providers in Massachusetts.

Other internal medicine in Milton

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →